No abstract

The combined score of these markers could be used to stratify biomolecular risk groups.

BACKGROUNDThe optimal chemotherapy regimen for the treatment of olfactory neuroblastoma has not been clearly defined. The purpose of the current study was to evaluate the efficacy of neoadjuvant chemotherapy with the combination of etoposide, ifosfamide, and cisplatin (VIP) for patients with olfactory neuroblastoma.METHODSEleven consecutive patients with newly diagnosed olfactory neuroblastoma were treated with etoposide (75 mg/m2), ifosfamide (1000 mg/m2), and cisplatin (20 mg/m2) all administered intravenously on Days 1–5. Cycles were repeated every 21 days. Patients were excluded from analysis if they had previously received surgery or radiotherapy.RESULTSNine patients achieved objective responses (objective response rate, 82%; 95% confidence interval, 52–95%), which included 2 complete responses and 7 partial responses. The major side effect was hematologic toxicity, with Grade 3/4 neutropenia observed after the receipt of 37% of all cycles and febrile neutropenia observed after the receipt of 2 cycles. All toxic events were reversible, and no chemotherapy‐related deaths were documented. The median survival period was 18 months (range, 3–45 months).CONCLUSIONSNeoadjuvant VIP chemotherapy was active in the treatment of olfactory neuroblastoma. Cancer 2004. © 2005 American Cancer Society.

The treatment outcome was poor and local control was a major problem. High radiation dose, effective chemotherapy and elective neck irradiation for advanced nasal cavity cancers may improve disease control.